IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Iambic Therapeutics, Inc.
$16.34−7.47 (-31.37%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Iambic Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Iambic Therapeutics, Inc. is listed on Nasdaq under the ticker IAM, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Iambic Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 5627 Oberlin Drive, Suite 120 92121
- Phone
- (626) 592-2520
- Website
- iambic.ai
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- IAM
- Exchange
- Nasdaq
- IPO date
- Oct 15, 2026
- SEC CIK
- 1997038
- EIN
- 84-3364168
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Iambic Therapeutics's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 15, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |